Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desmopressin
- Development stage
- Approved
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Desmopressin is a synthetic analog of the natural hormone vasopressin (antidiuretic hormone, ADH). It acts primarily as an antidiuretic by selectively stimulating V2 receptors in the renal collecting ducts, leading to increased water reabsorption and reduced urine production. Desmopressin is used to treat central diabetes insipidus, primary nocturnal enuresis (bedwetting), nocturia due to nocturnal polyuria in adults, and for certain bleeding disorders such as mild hemophilia A and type 1 von Willebrand disease. In bleeding disorders, it increases plasma levels of factor VIII and von Willebrand factor by promoting their release from endothelial storage sites[1][4][6][7]. The drug has minimal pressor activity compared to endogenous vasopressin due to its selectivity for V2 over V1 receptors.
- Brand names
- DDAVPNocdurnaMinirinStimateOctostim
- Other names
- desmopressin acetatedDAVP
02
Targets
AVPR1A (Arginine vasopressin receptor 1A)AVPR2 (Arginine vasopressin V2 receptor)
Beyond the preview
Go deeper on desmopressin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desmopressin.